A panel of the World Health Organization said on Friday that Gilead’s drug Remedisvir is not for Kovid-19 patients admitted to the hospital, no matter how ill they are. The panel said that there is no evidence to say that the drug improves the patient’s condition or the drug reduces the need for ventilation. Guidelines stated that the panel found a lack of evidence suggesting that Remedisvir reduced mortality or reduced the need for ventilation. These guidelines are a major setback for medicine. It is this drug that gained worldwide attention and showed some promise as a potentially effective treatment for Kovid-19 in the summer after initial testing.
In late October, Gilead cut its 2020 revenue forecast, citing lower demand and difficulty than Remedisvir’s sales forecast. The antiviral drug is one of only two drugs authorized to treat Kovid-19 patients worldwide, but a large WHO-led trial known as the Solidarity Trial last month showed that at 28-day mortality or length It had little or no effect.
The drug was one of the drugs used to treat US President Donald Trump’s coronavirus infection, and previous studies have shown that the drug cut recovery time. It is authorized for use as a Kovid-19 treatment in more than 50 countries. Gilead has questioned the results of the Solidarity trial. The WHO’s Guidelines Development Group (GDG) panel said its recommendation was based on a review of evidence that included data from four international randomized trials involving more than 7,000 patients hospitalized with Kovid-19.
After reviewing the evidence, the panel said, it has been concluded that Remedisvir has no meaningful effect on mortality or other significant outcomes for patients and is expensive and complex to administer. Following WHO’s latest advice representing intensive care doctors in the world’s top bodies stated that ish medicine should not be used for Kovid-19 patients in critical care wards.
Also read- New mask with anti-viral layer can neutralize corona virus: Study
The WHO recommendation, which is not binding, is part of its so-called “Survival Guidelines” project, designed to provide guidance for doctors about patients in rapidly growing conditions such as the Kovid-19 epidemic. To help in clinical decision making. Guidelines can be changed when new evidence and information are revealed. The panel said it supported continuing enrollment in clinical trials evaluating remedisvir in patients with COVID-19, stating that it “should provide high evidence for specific groups of patients.”